



Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution

March 13, 2023

PARIS, France, March 13, 2023 – 12:00 p.m. (CET) – Abivax SA (the “Company”, Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, is aware that Silicon Valley Bank (“SVB”) was closed on March 10, 2023, by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver.

The Company does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution, and it does not have any banking relationship with SVB. The Company has no exposure to any liquidity concern at SVB or any other U.S. financial institution.

About Abivax (www.abivax.com)

Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter [@ABIVAX_](https://twitter.com/ABIVAX_).

Contacts

**Abivax
Communications**
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63

**Investors
LifeSci Advisors**
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310

**Press Relations & Investors Europe
MC Services AG**
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

**Public Relations France
Actifin**
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24

**Public Relations France
Primatice**
Thomas Roborel de Climens
thomasdeclimens@primatice.com
+33 6 78 12 97 95

**Public Relations USA
Rooney Partners LLC**
Jeanene Timberlake
jtimberlake@rooneypartners.com
+1 646 770 8858